Effect of metformin on patients with polycystic ovary syndrome
Abstract
Aim: To investigate the effect of metformin on patients with polycystic ovary syndrome (PCOS). Methods: A total of 24 patients with PCOS received metformin at 1 500 mg per day for six months. Serum levels of luteinizing hormone (LH), testosterone(T), OGTT, and releasing insulin were measured before and after treatment and 4 months after withdrawal of metformin. The menses and ovulation were observed.Results: A total of 17 cases (70.8%) patients resumed regular menstrual cycles with ovulation, and the serum levels of LH, T, fasting insulin and the areas below the insulin releasing curve decreased significantly (P0.05). At 4 months after withdrawal of metformin treatment a reversal was observed.Conclusion: Metformin is an effective drug for PCOS, but the symptoms will recur before long after the withdrawal of metformin, which suggests that patients should keep using it during pregnancy.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.